1,763,505 Shares in Evelo Biosciences Inc (EVLO) Purchased by HarbourVest Partners LLC

Share on StockTwits

HarbourVest Partners LLC purchased a new position in shares of Evelo Biosciences Inc (NASDAQ:EVLO) in the second quarter, HoldingsChannel reports. The fund purchased 1,763,505 shares of the company’s stock, valued at approximately $20,809,000. Evelo Biosciences comprises about 26.3% of HarbourVest Partners LLC’s portfolio, making the stock its largest holding. HarbourVest Partners LLC owned approximately 0.06% of Evelo Biosciences as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Flagship Pioneering Inc. acquired a new stake in shares of Evelo Biosciences in the 2nd quarter valued at approximately $215,154,000. FMR LLC acquired a new stake in shares of Evelo Biosciences in the 2nd quarter valued at approximately $36,832,000. BlackRock Inc. acquired a new stake in shares of Evelo Biosciences in the 2nd quarter valued at approximately $3,090,000. Laurion Capital Management LP acquired a new stake in shares of Evelo Biosciences in the 2nd quarter valued at approximately $1,770,000. Finally, ARK Investment Management LLC acquired a new stake in shares of Evelo Biosciences in the 2nd quarter valued at approximately $1,497,000. 80.51% of the stock is owned by hedge funds and other institutional investors.

NASDAQ EVLO opened at $13.38 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.08 and a current ratio of 24.08. Evelo Biosciences Inc has a 12 month low of $11.10 and a 12 month high of $16.75.

Evelo Biosciences (NASDAQ:EVLO) last posted its quarterly earnings results on Thursday, August 2nd. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.49). sell-side analysts predict that Evelo Biosciences Inc will post -1.88 EPS for the current fiscal year.

Several equities research analysts have recently commented on the company. Morgan Stanley assumed coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “overweight” rating for the company. Cowen assumed coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating for the company. BMO Capital Markets assumed coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating and a $26.00 price objective for the company. Finally, JMP Securities assumed coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating and a $25.00 price objective for the company.

About Evelo Biosciences

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.

Recommended Story: Diversification in Your Portfolio

Want to see what other hedge funds are holding EVLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evelo Biosciences Inc (NASDAQ:EVLO).

Institutional Ownership by Quarter for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply